Related Experiment Videos
Losigamone. Dr Willmar Schwabe
1Department of Neurology, Saint Louis University School of Medicine, MO 63104, USA. willmore@slu.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
Summary
Losigamone is an antiepileptic drug in development. Its exact mechanism is unclear, but it may involve K+ channel activation rather than direct GABA receptor interaction.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Development
Background:
- Losigamone is an investigational antiepileptic drug developed by Schwabe.
- The drug was in phase III clinical trials as of August 2000.
- Schwabe was seeking partners for further development and trial completion.
Purpose of the Study:
- To investigate the pharmacological profile and mechanism of action of losigamone.
- To clarify losigamone's interaction with GABAergic systems and ion channels.
Main Methods:
- In vitro studies examining interactions with GABA, flunitrazepam, and TBPS receptors.
- Electrophysiological recordings in hippocampal slices to assess effects on inhibitory postsynaptic potentials (IPSPs).
- Assays measuring GABA-induced chloride influx in primary neuron cultures.
Main Results:
- Losigamone does not appear to involve specific binding to GABA, flunitrazepam, or TBPS receptors.
- Conflicting data exist regarding its interaction with GABA-A receptor channels.
- It did not significantly alter GABAergic IPSPs in hippocampal slices.
- However, it potentiated GABA-induced chloride influx in spinal cord neuron cultures.
- K+ channel activation is a suggested alternative mechanism.
Conclusions:
- The precise mechanism of action for losigamone remains undetermined.
- Evidence suggests it may not act via direct binding to common GABA receptor sites.
- Potential roles in modulating GABAergic transmission and K+ channel activity warrant further investigation.